Lukasz Kuzma/LinkedIn
Feb 16, 2026, 14:44
Lukasz Kuzma: NOAC Monotherapy vs NOAC Plus Clopidogrel in AF Beyond One Year After DES
Lukasz Kuzma, Research Professor at University of Liverpool, shared a post on X about a recent article he and his colleague co-authored, adding:
“In our NEJM editorial with ESC Stroke Chair, we highlight the first RCT in AF more than 1 year after DES showing that NOAC monotherapy was not noninferior and statistically superior to NOAC plus clopidogrel for net adverse clinical events also with less bleeding.”
Title: Thromboprophylaxis for Atrial Fibrillation in Patients with Drug-Eluting Stents
Authors: Gregory Y.H. Lip and Lukasz Kuzma
Read the Full Article on The New England Journal of Medicine.
Stay updated with Hemostasis Today.
-
Oct 14, 2026, 18:20Yuria Ito: Does an MCV Below 100 Mean There Is No Vitamin B12 Deficiency?
-
Oct 14, 2026, 18:08Micheal Avoseh: Nanoparticle Research for Venous Thrombosis
-
Oct 14, 2026, 18:00A Decade of Symptoms Before a Rare Disease Diagnosis – ITP Support Association
-
Oct 14, 2026, 17:52David McIntosh: The Global Blood Shortage and the Need for Sustainable Donor Recruitment
-
Oct 14, 2026, 17:41Emmanuel J Favaloro։ October 13 is World Thrombosis Day
-
Oct 14, 2026, 17:24EHC ERIN Webinar on Fibrinogen Disorders
-
Oct 14, 2026, 16:50Peter Kouides: The Role of Multidisciplinary Networks in Women’s Hematologic Care
-
Oct 14, 2026, 16:35Thaís Leonel: Analytical Consistency as a Foundation for Evidence-Based Thrombosis Management
-
Oct 14, 2026, 16:28Christina Yiangou: Presenting the HemaFAIR Project at ASCAT 2026 in London